PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jkcvhlJournal of Kidney Cancer and VHL
 
J Kidney Cancer VHL. 2017; 4(1): 16–24.
Published online 2017 March 21. doi:  10.15586/jkcvhl.2017.64
PMCID: PMC5364332

Maslinic Acid Inhibits Proliferation of Renal Cell Carcinoma Cell Lines and Suppresses Angiogenesis of Endothelial Cells

Abstract

Despite the introduction of many novel therapeutics in clinical practice, metastatic renal cell carcinoma (RCC) remains a treatment-resistant cancer. As red and processed meat are considered risk factors for RCC, and a vegetable-rich diet is thought to reduce this risk, research into plant-based therapeutics may provide valuable complementary or alternative therapeutics for the management of RCC. Herein, we present the antiproliferative and antiangiogenic effects of maslinic acid, which occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants. Human RCC cell lines (ACHN, Caki-1, and SN12K1), endothelial cells (human umbilical vein endothelial cell line [HUVEC]), and primary cultures of kidney proximal tubular epithelial cells (PTEC) were treated with maslinic acid. Maslinic acid was relatively less toxic to PTEC when compared with RCC under similar experimental conditions. In RCC cell lines, maslinic acid induced a significant reduction in proliferation, proliferating cell nuclear antigen, and colony formation. In HUVEC, maslinic acid induced a significant reduction in capillary tube formation in vitro and vascular endothelial growth factor. This study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing antiangiogenic therapy to improve efficacy.

Keywords: angiogenesis, maslinic acid, proliferating cell nuclear antigen, renal cell carcinoma, vascular endothelial growth factor

Introduction

Renal cell carcinoma (RCC) is a highly metastatic, heterogeneous disease that is resistant to conventional treatment modalities. In the past decade, the introduction of many novel targeted therapeutics, mostly tyrosine kinase inhibitors (TKIs) targeting the angiogenesis pathway, has marginally increased progression-free and overall survival rates (1, 2). Resistance to therapy continues to be a major challenge in the effective treatment of metastatic RCC patients (3, 4). About 30% of patients are inherently resistant to TKIs, and the remaining 70% who initially respond to treatment eventually develop resistance (5–7). There is an immense need to find novel anticancer agents to combat this deadly disease. The contribution of plant-derived natural products to cancer therapy has been widely acknowledged (8). The best examples are the taxanes paclitaxel and docetaxel, derived from the genus Taxus (9).

Research into plant-based potential alternative or complementary therapies is particularly important given that red and processed meat are thought to be risk factors for the development of RCC (10–12) and that a vegetable-rich diet is considered to reduce the risk (13, 14). Maslinic acid is a pentacyclic triterpenoid that occurs naturally in edible plants, particularly in olive fruits, and also in a variety of medicinal plants (15, 16). Maslinic acid has been shown to have antioxidant (17), anti-inflammatory (18), antimalarial (19), antiprotozoan (20), antidiabetic (21), and anti–HIV-1 activities (22). In addition, in vitro, maslinic acid has been shown to exert proapoptotic effects on many human cancer cell lines including colon (15), prostate (23), bladder (24), and lung (25). The predominant mechanism appears to be induction of apoptosis through the inhibition of various antiapoptotic molecules including nuclear factor-κB and the antiapoptotic Bcl-2 family members (15, 26). To our knowledge, the effect of maslinic acid on RCC has not been reported. In the current study, we explored the anticancer and antiangiogenic effects of maslinic acid in RCC cell lines and endothelial cells, respectively. Maslinic acid exerted significant anticancer and antiangiogenic properties. The major mechanism appears to be inhibition of proliferation rather than induction of apoptosis.

Materials and Methods

Ethics approval

Approvals for the collection and use of primary cultures of human proximal tubular epithelial cells were obtained from the Human Research Ethics Committee of the Princess Alexandra Hospital and the Human Ethics Committee of University of Queensland, Brisbane, Australia. Written informed consent was obtained from patients before the collection of samples.

Cells and compounds

Maslinic acid (>98% purity) was purchased from Sigma-Aldrich (St. Louis, MO; Cat No. M6699-5MG). Maslinic acid was dissolved in dimethyl sulfoxide (DMSO) and further diluted in cell culture medium to the desired concentration. The compound was freshly prepared immediately before use. The human RCC cell lines ACHN and Caki-1, and the human umbilical vein endothelial cell (HUVEC) line were obtained from ATCC. Another human metastatic RCC cell line, SN12K1, was obtained from Professor D. Nicol, formerly at Princess Alexandra Hospital, Brisbane, Australia, through his collaborations with Dr I. J. Fidler, Cancer Research Institute, MD Anderson Cancer Center, Orlando, FL. Primary cultures of morphologically normal human kidney proximal tubular epithelial cells (PTECs) were isolated and maintained as per our previous publication (27). The RCC cell lines were maintained as a monolayer in DMEM/F12 (Gibco; Invitrogen, Carlsbad, CA) containing 10% fetal bovine serum (Gibco; Invitrogen, Carlsbad, CA) supplemented with 50-U/ml penicillin and 50-µg/ml streptomycin, at 37°C in a humidified atmosphere of 5% CO2/95% air.

MTT Assay for Cell Viability

Cell viability in response to maslinic acid treatment was analyzed as per our previous report (28). In brief, 3 × 103 cells per well per 100 µl were seeded in 96-well culture plates and incubated for 24 hours. The cells were treated with various concentrations of maslinic acid, and after 24 hours of incubation, 5 µl of MTT, from a stock of 5 mg/ml in phosphate buffered saline (PBS), was added to each well and incubated for 90 minutes at 37°C in a humidified atmosphere of 5% CO2/95% air. After the incubation period, the culture medium was removed and the purple crystals formed were dissolved in 100 µl of DMSO. The absorbance was recorded using a microplate reader at 570 nm with a reference wavelength of 690 nm. The IC50 values were calculated from the absorbance.

Assessment of Apoptosis and Proliferation

Morphological assessment of apoptosis and proliferation was performed as per previous publication (28). In brief, 5 × 104 cells were seeded on a cover slip in 24-well culture plates. After 24 hours, cells were treated with their respective IC50 values of maslinic acid. After an incubation period of 24 hours, the culture medium was removed, and cells were fixed with 4% formalin. Hematoxylin and eosin staining was performed to study the morphology of proliferating cells and apoptotic cells. The cells were viewed under a 40× microscope objective, and the cells that fell within the 100 squares of an eye graticule were counted. Apoptotic nuclei were determined based on their distinct morphological features: hyperchromasia, shrunken/ condensed nuclei, blebbing of the membrane while maintaining membrane integrity, crescent nuclei, and apoptotic bodies (29). Proliferating cells were identified by the conspicuous visibility of chromosomes, various stages of mitosis with a visible metaphase plate, and cytokinesis. Apoptotic and proliferating cells were expressed as a percentage of the total cells counted from five random fields for each cover slip.

Colony formation assay

Colony formation assay of RCC cell lines was performed as per our previous publication (30). Briefly, 1 × 103 RCC cells were seeded in six-well plates. Three hours later, the culture medium was removed and the plates were washed with culture medium to remove unattached cells. The cells were incubated in culture medium with or without maslinic acid and cultured for 10 days. The medium was removed at the end of experiments, the cells were washed in PBS, fixed in 4% formalin, washed in PBS, and stained with 0.5% crystal violet aqueous stain. The cells were washed until no stain came out, air dried, and photographed. The dye was extracted using DMSO and then quantified using a spectrophotometer at 590 nm.

In vitro angiogenesis

An in vitro angiogenesis assay was performed as described previously (31). Briefly, 96-well plates were coated with 50 µl of Matrigel (BD Biosciences, North Ryde, NSW, Australia) and allowed to solidify for 60 minutes at 37°C. HUVEC were dispersed in culture medium with or without maslinic acid (24 µM, which is half the IC50 value for HUVEC). The cells were then seeded on the Matrigel at a density of 3 × 104 cells/100 µl. After 6 hours, the cells were photographed under a phase-contrast microscope. The number of tubes and the average length of tube per field were determined.

Gene expression studies

Cells were grown to approximately 90% confluence in 6-cm petri dishes and treated with or without maslinic acid. Twenty-four hours later, total RNA was isolated using PureLink RNA Mini Kit (Life Technologies, VIC, Australia) as per the manufacturer’s protocol and quantified with Nano drop (Thermo Fisher Scientific, VIC, Australia). cDNA was synthesized using a High Capacity cDNA Reverse Transcription Kit (Life Technologies). In brief, 1 µg of RNA in a RT-PCR reaction mixture (2 µl 10× buffer, 0.8 µl dNTP, 2 µl r-hex, 1 µl enzyme, water to 20 µl per reaction) was subjected to the following PCR conditions: 25°C for 10 minutes, 37°C for 120 minutes, 85°C for 5 minutes followed by holding at 4°C. The cDNA was diluted to 50 µl with 30 µl of RNAse-free water. Fully validated TaqMan Gene Expression Assay (Life Technologies) for vascular endothelial growth factor A (VEGFA; Hs00900055_m1), interleukin-6 (IL-6; Hs00985639_m1), interleukin-8 (IL-8; Hs00174103_m1), proliferating cell nuclear antigen (PCNA; Hs00427214_g1), Bcl2-associated X protein (BAX; Hs00180269_m1), B-cell lymphoma 2 (Bcl2; Hs00236808_s1), and tight junction protein 1 (TJP-1; Hs01551861_m1) was used with SensiFAST™ Probe No-ROX Kit (Bioline, London, UK) in a LightCycler 480 (Roche Applied Science, Penzberg, Germany) to determine relative gene expression by the comparative Ct method. The TATA box binding protein (TBP Hs00427620_m1; Life Technologies) was used as internal control, and for normalization.

Statistical analyses

The data were analyzed using Student’s t-test, and P < 0.05 was considered significant. The experiments were performed in duplicates with n = 6 for each set. The results are expressed as mean ± standard error.

Results

Maslinic acid is toxic to RCC cell lines

The IC50 values of the RCC cell lines and PTEC, after 24 hours of treatment with maslinic acid, are shown in Table 1. Of the three RCC cell lines, SN12K1 was the most susceptible with an IC50 value of 47.11 µM and ACHN was the most resistant with an IC50 value of 76.52 µM. As toxicity is one of the major limiting factors in conventional chemotherapy, it was essential to test the toxicity of maslinic acid in noncancerous, morphologically normal proximal tubular cells. As expected, PTEC from nine donors showed varying responses. Although all PTEC showed a higher IC50 value than SN12K1, demonstrating selective toxicity of maslinic acid to this cell RCC cell type, five of nine PTEC (PTEC 4, 6, 7, 8, and 9) showed a higher IC50 value than ACHN and Caki-1. Thus, maslinic acid is relatively less toxic to PTEC when compared with RCC under similar experimental conditions. For further experiments, the respective IC50 values of each RCC cell lines were used.

Table 1.
IC50 values of cells

Maslinic acid did not induce apoptosis in RCC cell lines

To find the mechanism of maslinic acid–induced cytotoxicity, the proapoptotic effect of maslinic acid on the RCC cells was studied. After 24 hours of treatment, maslinic acid did not induce any significant changes in apoptosis (Figure 1A). To further confirm these findings at a molecular level, expression of the antiapoptotic gene Bcl2 and the proapoptotic gene Bax was studied by validated human TaqMan primers. No significant changes in the expression of Bcl2 (Figure 1B) or Bax (Figure 1C) were observed in response to maslinic acid treatment.

Figure 1.
Lack of effect of maslinic acid on apoptosis and apoptosis-regulatory molecules. The effect of maslinic acid on apoptosis of RCC was studied 24 hours after incubating the cells with maslinic acid. Morphologically, maslinic acid did not induce any significant ...

Maslinic acid decreased the proliferation of RCC cell lines

To further verify the mechanisms of maslinic acid–induced cytotoxicity, the antiproliferative activity of maslinic acid was studied. A significant decrease in proliferation of RCC cells was observed in response to maslinic acid (Figure 2A). A representative area from untreated cells and cells treated with maslinic acid is demonstrated (Figure 2B). To further confirm these findings at the molecular level, the expression of PCNA was studied by quantitative PCR using validated primers. A significant decrease in PCNA was observed in cells treated with maslinic acid (Figure 2C). Thus, the main mechanism of maslinic acid–induced cytotoxicity appears to be inhibition of proliferation rather than induction of apoptosis or cell death.

Figure 2.
Maslinic acid significantly reduced the proliferation of RCC cells. Twenty-four hours after treatment, maslinic acid induced a significant reduction in proliferation of all three RCC cell lines (A). Representative images of untreated cells and cells treated ...

Maslinic acid inhibited colony formation

Once a cell has detached from a primary tumor, it must attach to a distant part of the body to grow and metastasise. The colony formation assay is one of the measures to study adhesion. Maslinic acid induced a significant decrease in colony formation of ACHN, Caki-1, and SN12K1 cell lines (Figure 3). The number of colonies in the treated and nontreated groups appeared similar although the size of the colonies was smaller in the treated groups, further confirming the antiproliferative effect of maslinic acid. Quantification of the dye showed a significant decrease in cells treated with maslinic acid (graphs on the right side beside each photograph). Analysis of some of the molecular markers, TJP-1 (Figure 4A), IL-6 (Figure 4B), IL-8 (Figure 4C), and VEGF (Figure 4D), implicated in adhesion and metastasis, showed no significant changes between the control and treatment groups.

Figure 3.
Maslinic acid significantly reduced colony formation. Adhesion and colony formation are essential steps in distant metastasis. Maslinic acid significantly decreased colony formation of all three cell lines. Left, representative images showing colony formation. ...
Figure 4.
Lack of effect of maslinic acid on markers of RCC progression. Analysis of TJP-1 (A), the IL-6 (B), IL-8 (C), and VEGF (D) did not show any significant changes in response to maslinic acid. These results further confirm that the primary effect of maslinic ...

Maslinic acid inhibited in vitro angiogenesis

The antiangiogenic activity of maslinic acid was studied using an in vitro tube formation assay in HUVEC. Maslinic acid significantly decreased tube formation of HUVEC (Figure 5A and B). Quantification showed a significant decrease in the number (Figure 5C) and the length (Figure 5D) of tubes. To verify that the observed effect of maslinic acid was antiangiogenesis per se, not cell death, an MTT assay was performed. For this, HUVEC were dispersed in culture medium with or without maslinic acid (24 µM). The cells were then seeded on 96-well plates at a density of (3 × 104 cells/100 µl). After 6 hours, the MTT assay was performed as described previously. No significant death of HUVEC was observed (Figure 5E), confirming independent antiangiogenic activity. To elucidate the molecular mechanism, the expression VEGF was studied. A significant decrease in VEGF was observed in response to maslinic acid (Figure 5F).

Figure 5.
Maslinic acid inhibited in vitro angiogenesis. HUVEC in the untreated group formed enclosed network like structures (A), which was prevented by maslinic acid (B). Average number of tubes per field (C) and tube length (D) expressed as percentage in relation ...

Discussion

Despite the introduction of many targeted therapies in the past decade, metastatic RCC continues to be a treatment-resistant malignancy. A need exists for the identification of more effective novel therapeutics. Plant-based natural compounds as anticancer agents have been a subject of intense research and have produced some positive outcomes in the past as exemplified by the taxanes (9). Herein, we studied the anticancer effect of maslinic acid, a naturally occurring pentacyclic triterpenoid found abundantly in olives and many other plants (16), with emphasis on apoptosis and proliferation of RCC cell lines and angiogenesis of endothelial cells.

A defective apoptotic pathway is one of the hallmarks of cancer (32) and is thought to regulate cancer biology by at least two mechanisms: failure to remove aberrant cells and providing resistance to chemotherapy. The two major pathways of apoptosis regulation are the extrinsic or the death-receptor pathway, and the intrinsic or the mitochondrial pathway (33, 34). The extrinsic pathway induces apoptosis through cleavage of caspase, whereas the intrinsic pathway exerts apoptosis through the modulation of the Bcl2 family of apoptosis-regulatory molecules (34). The proapoptotic effect of maslinic acid has been extensively studied in many cancer cells. Some of the reported mechanisms include the downregulation of the antiapoptotic Bcl2 molecules and inhibitor of apoptosis proteins and the upregulation of the proapoptotic molecules such as Bax, cleaved caspase-3, caspase-8, and caspase-9 (15, 35). In our study, contrary to the proapoptotic effect reported for other cancer cells, maslinic acid did not demonstrate any significant proapoptotic effects, either morphologically or at molecular level. To further investigate the mechanism of action maslinic acid, we focused on the effect on proliferation.

Maslinic acid induced a significant decrease in proliferation of the RCC cells: morphologically by a lower number of mitotic cells, reduced size of colonies, and molecularly by decreased PCNA expression. PCNA plays a crucial role in cell cycle and proliferation by appearing in the nucleus during the late G1 phase, increasing during the S phase, and decreasing during the G2 and M phases (36). RCC is a highly metastatic disease, and a higher expression of PCNA is thought to be an indicator of unfavorable prognosis (37). Expression of PCNA is associated with the expression of epidermal growth factor receptor, which itself is a survival factor for many cancers, including RCC. PCNA is also associated with the MYC pathway and is the target molecule of pro-oncogenic MYC. Knockdown of MYC has been shown to suppress the proliferation of clear cell RCC (38). Thus, maslinic acid may directly inhibit RCC progression via the reduction of PCNA and indirectly by reducing the substrate of other oncogenic molecules. The expression pattern of TJP-1, IL-6, IL-8, and VEGF, some of the most studied molecules that are well-known players in RCC progression, showed no significant changes in response to maslinic acid.

After verifying that the mechanism of action of maslinic acid is mediated via the inhibition of proliferation rather than the induction of apoptosis, we explored its antiangiogenic actions. Due to aberrations in von Hippel Lindau gene, and subsequent activation of downstream hypoxia-inducible proangiogenic factors, RCC is one of the most vascularized solid tumors (39). The majority of the targeted therapies introduced in clinical practice in the past decade are multi-TKIs, targeting the angiogenesis pathway (40). In vitro capillary tube formation assay showed that maslinic acid has antiangiogenic effects independent of its cytotoxic effects. At the molecular level, it significantly inhibited VEGF, the prime mediator of angiogenesis. VEGF expression has a correlation with tumor microvascular density, disease progression, and metastasis of RCC (41–43).

In summary, maslinic acid exerts antiproliferative and antiangiogenic activities. The putative mechanisms of action of maslinic acid, based on our results, are summarized in Figure 6. Our results on antiangiogenic and antiproliferative activities are in line with previously published reports of maslinic acid (23–26, 44) and other pentacyclic triterpenoic acids such as ursolic acid and oleanolic acid (44–47). It is well known that tumor type is a determinant of susceptibility to apoptosis (48) and that compounds can exert cell-specific apoptosis (49). We believe that this may be a reason why maslinic acid did not induce apoptosis in RCC cells.

Figure 6.
Putative role of maslinic acid on proliferation and angiogenesis. Aberrations of von Hippel-Lindau gene (VHL) are the major risk factors for RCC. Inactivated VHL leads to the upregulation of hypoxia-inducible factor (HIF), which in turn leads to the upregulation ...

In conclusion, this study provides a rationale for incorporating a maslinic acid–rich diet either to reduce the risk of developing kidney cancer or as an adjunct to existing anticancer therapy, particularly antiangiogenic therapies, to improve efficacy. Considering the need for alternative and complementary therapies for RCC, further studies are warranted to explore the antiproliferative and antiangiogenic potential of maslinic acid as a therapeutic agent for RCC.

Acknowledgments

The authors are thankful to Translational Research Institute, Brisbane core microscopy facility. P. Thakor is thankful to the Department of Education, Australia, for an Endeavour Award and DST India for an Inspire Fellowship (DST INSPIRE FELLOWSHIP/2013/44).

Conflicts of interest

The authors declare no potential conflicts of interest with respect to research, authorship, and/or publication of this article.

References

1. Soerensen AV, Donskov F, Hermann GG, Jensen NV, Petersen A, Spliid H, et al. Improved overall survival after implementation of targeted therapy for patients with metastatic renal cell carcinoma: results from the Danish Renal Cancer Group (DARENCA) study-2. Eur J Cancer. 2014;50(3):553–62. http://dx.doi.org/10.1016/j.ejca.2013.10.010. [PubMed]
2. Koshkin VS, Rini BI. Emerging therapeutics in refractory renal cell carcinoma. Expert Opin Pharmacother. 2016;17(9):1225–32. http://dx.doi.org/10.1080/14656566.2016.1182987. [PubMed]
3. Jiménez-Valerio G, Martínez-Lozano M, Bassani N, Vidal A, Ochoa-de-Olza M, Suárez C, et al. Resistance to antiangiogenic therapies by metabolic symbiosis in renal cell carcinoma PDX models and patients. Cell Rep. 2016;15(6):1134–43. http://dx.doi.org/10.1016/j.celrep.2016.04.015. [PMC free article] [PubMed]
4. Lim SH, Hwang IG, Ji JH, Oh SY, Yi JH, Lim DH, et al. Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma. Asia Pac J Clin Oncol. 2017;13(1):61–67. http://dx.doi.org/10.1111/ajco.12465. [PubMed]
5. Rini BI, Atkins MB. Resistance to targeted therapy in renal-cell carcinoma. Lancet Oncol. 2009;10(10):992–1000. http://dx.doi.org/10.1016/S1470-2045(09)70240-2. [PubMed]
6. Porta C, Sabbatini R, Procopio G, Paglino C, Galligioni E, Ortega C. Primary resistance to tyrosine kinase inhibitors in patients with advanced renal cell carcinoma: state-of-the-science. Expert Rev Anticancer Ther. 2012;12(12):1571–7. http://dx.doi.org/10.1586/era.12.81. [PubMed]
7. Busch J, Seidel C, Weikert S, Wolff I, Kempkensteffen C, Weinkauf L, et al. Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma. BMC Cancer. 2011;11:295. http://dx.doi.org/10.1186/1471-2407-11-295. [PMC free article] [PubMed]
8. Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R. Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci. 2009;5(1):1–11. [PMC free article] [PubMed]
9. Joshi M, Liu X, Belani CP. Taxanes, past, present, and future impact on non-small cell lung cancer. Anticancer Drugs. 2014;25(5):571–83. http://dx.doi.org/10.1097/CAD.0000000000000080. [PubMed]
10. Rohrmann S, Linseisen J, Overvad K, Lund Würtz AM, Roswall N, Tjonneland A, et al. Meat and fish consumption and the risk of renal cell carcinoma in the European prospective investigation into cancer and nutrition. Int J Cancer. 2015;136(5):E423–31. http://dx.doi.org/10.1002/ijc.29236. [PubMed]
11. Daniel CR, Schwartz KL, Colt JS, Dong LM. Meat-cooking mutagens and risk of renal cell carcinoma. Br J Cancer. 2011;105(7):1096–104. http://dx.doi.org/10.1038/bjc.2011.343. [PMC free article] [PubMed]
12. Hsu CC, Chow WH, Boffetta P, Moore L, Zaridze D, Moukeria A, et al. Dietary risk factors for kidney cancer in Eastern and Central Europe. Am J Epidemiol. 2007;166(1):62–70. http://dx.doi.org/10.1093/aje/kwm043. [PubMed]
13. Grieb SM, Theis RP, Burr D, Benardot D, Siddiqui T, Asal NR. Food groups and renal cell carcinoma: results from a case-control study. J Am Diet Assoc. 2009;109(4):656–67. http://dx.doi.org/10.1016/j.jada.2008.12.020. [PubMed]
14. Rashidkhani B, Lindblad P, Wolk A. Fruits, vegetables and risk of renal cell carcinoma: a prospective study of Swedish women. Int J Cancer. 2005;113(3):451–5. http://dx.doi.org/10.1002/ijc.20577. [PubMed]
15. Reyes-Zurita FJ, Rufino-Palomares EE, Lupianez JA, Cascante M. Maslinic acid, a natural triterpene from Olea europaea L., induces apoptosis in HT29 human colon-cancer cells via the mitochondrial apoptotic pathway. Cancer Lett. 2009;273(1):44–54. http://dx.doi.org/10.1016/j.canlet.2008.07.033. [PubMed]
16. Lozano-Mena G, Sanchez-Gonzalez M, Juan ME, Planas JM. Maslinic acid, a natural phytoalexin-type triterpene from olives–a promising nutraceutical? Molecules. 2014;19(8):11538–59. http://dx.doi.org/10.3390/molecules190811538. [PubMed]
17. Montilla MP, Agil A, Navarro MC, Jiménez MI, García-Granados A, Parra A, et al. Antioxidant activity of maslinic acid, a triterpene derivative obtained from Olea europaea. Planta Med. 2003;69(5):472–4. http://dx.doi.org/10.1055/s-2003-39698. [PubMed]
18. Huang L, Guan T, Qian Y, Huang M, Tang X, Li Y, et al. Anti- inflammatory effects of maslinic acid, a natural triterpene, in cultured cortical astrocytes via suppression of nuclear factor-kappa B. Eur J Pharmacol. 2011;672(1–3):169–74. http://dx.doi.org/10.1016/j.ejphar.2011.09.175. [PubMed]
19. Moneriz C, Mestres J, Bautista JM, Diez A, Puyet A. Multi-targeted activity of maslinic acid as an antimalarial natural compound. FEBS J. 2011;278(16):2951–61. http://dx.doi.org/10.1111/j.1742-4658.2011.08220.x. [PubMed]
20. De Pablos LM, González G, Rodrigues R, García Granados A, Parra A, Osuna A. Action of a pentacyclic triterpenoid, maslinic acid, against Toxoplasma gondii. J Nat Prod. 2010;73(5):831–4. http://dx.doi.org/10.1021/np900749b. [PubMed]
21. Liu J, Sun H, Duan W, Mu D, Zhang L. Maslinic acid reduces blood glucose in KK-Ay mice. Biol Pharm Bull. 2007;30(11):2075–8. http://dx.doi.org/10.1248/bpb.30.2075. [PubMed]
22. Parra A, Rivas F, Lopez PE, Garcia-Granados A, Martinez A, Albericio F, et al. Solution- and solid-phase synthesis and anti-HIV activity of maslinic acid derivatives containing amino acids and peptides. Bioorg Med Chem. 2009;17(3):1139–45. http://dx.doi.org/10.1016/j.bmc.2008.12.041. [PubMed]
23. Park SY, Nho CW, Kwon DY, Kang YH, Lee KW, Park JH. Maslinic acid inhibits the metastatic capacity of DU145 human prostate cancer cells: possible mediation via hypoxia-inducible factor-1alpha signalling. Br J Nutr. 2013;109(2):210–22. http://dx.doi.org/10.1017/S0007114512000967. [PubMed]
24. Zhang S, Ding D, Zhang X, Shan L, Liu Z. Maslinic acid induced apoptosis in bladder cancer cells through activating p38 MAPK signaling pathway. Mol Cell Biochem. 2014;392(1–2):281–7. http://dx.doi.org/10.1007/s11010-014-2038-y. [PubMed]
25. Hsia TC, Liu WH, Qiu WW, Luo J, Yin MC. Maslinic acid induces mitochondrial apoptosis and suppresses HIF-1alpha expression in A549 lung cancer cells under normoxic and hypoxic conditions. Molecules. 2014;19(12):19892–906. http://dx.doi.org/10.3390/molecules191219892. [PubMed]
26. Li C, Yang Z, Zhai C, Qiu W, Li D, Yi Z, Wang L, et al. Maslinic acid potentiates the anti-tumor activity of tumor necrosis factor alpha by inhibiting NF-kappaB signaling pathway. Mol Cancer. 2010;9:73. http://dx.doi.org/10.1186/1476-4598-9-73. [PMC free article] [PubMed]
27. Morais C, Westhuyzen J, Pat B, Gobe G, Healy H. High ambient glucose is effect neutral on cell death and proliferation in human proximal tubular epithelial cells. Am J Physiol Renal Physiol. 2005;289(2):F401–9. http://dx.doi.org/10.1152/ajprenal.00408.2004. [PubMed]
28. Morais C, Pat B, Gobe G, Johnson DW, Healy H. Pyrrolidine dithiocarbamate exerts anti-proliferative and pro-apoptotic effects in renal cell carcinoma cell lines. Nephrol Dial Transplant. 2006;21(12):3377–88. http://dx.doi.org/10.1093/ndt/gfl543. [PubMed]
29. Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972;26(4):239–57. http://dx.doi.org/10.1038/bjc.1972.33. [PMC free article] [PubMed]
30. Morais C, Gobe G, Johnson DW, Healy H. Anti-angiogenic actions of pyrrolidine dithiocarbamate, a nuclear factor kappa B inhibitor. Angiogenesis. 2009;12(4):365–79. http://dx.doi.org/10.1007/s10456-009-9158-0. [PubMed]
31. Morais C, Ebrahem Q, Anand-Apte B, Parat MO. Altered angiogenesis in caveolin-1 gene-deficient mice is restored by ablation of endothelial nitric oxide synthase. Am J Pathol. 2012;180(4):1702–14. http://dx.doi.org/10.1016/j.ajpath.2011.12.018. [PubMed]
32. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. http://dx.doi.org/10.1016/j.cell.2011.02.013. [PubMed]
33. Nam YJ, Mani K, Ashton AW, Peng CF, Krishnamurthy B, Hayakawa Y, et al. Inhibition of both the extrinsic and intrinsic death pathways through nonhomotypic death-fold interactions. Mol Cell. 2004;15(6):901–12. http://dx.doi.org/10.1016/j.molcel.2004.08.020. [PubMed]
34. Ola MS, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis. Mol Cell Biochem. 2011;351(1–2):41–58. http://dx.doi.org/10.1007/s11010-010-0709-x. [PubMed]
35. Bai X, Zhang Y, Jiang H, Yang P, Li H, Zhang Y, et al. Effects of maslinic acid on the proliferation and apoptosis of A549 lung cancer cells. Mol Med Rep. 2016;13(1):117–22. [PMC free article] [PubMed]
36. Dirim A1, Haberal AN, Goren MR, Tekin MI, Peskircioglu L, Demirhan B, et al. VEGF, COX-2, and PCNA expression in renal cell carcinoma subtypes and their prognostic value. Int Urol Nephrol. 2008;40(4):861–8. http://dx.doi.org/10.1007/s11255-008-9362-7. [PubMed]
37. Amare Kadam PS, Varghese C, Bharde SH, Narasimhamoorthy NK, Desai S, Advani SH, et al. Proliferating cell nuclear antigen and epidermal growth factor receptor (EGFr) status in renal cell carcinoma patients with polysomy of chromosome 7. Cancer Genet Cytogenet. 2001;125(2):139–46. http://dx.doi.org/10.1016/S0165-4608(00)00375-7. [PubMed]
38. Tang SW, Chang WH, Su YC, Chen YC, Lai YH, Wu PT, et al. MYC pathway is activated in clear cell renal cell carcinoma and essential for proliferation of clear cell renal cell carcinoma cells. Cancer Lett. 2009;273(1):35–43. http://dx.doi.org/10.1016/j.canlet.2008.07.038. [PubMed]
39. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol. 2005;23(5):1028–43. http://dx.doi.org/10.1200/JCO.2005.01.186. [PubMed]
40. Posadas EM, Limvorasak S, Sharma S, Figlin RA. Targeting angiogenesis in renal cell carcinoma. Expert Opin Pharmacother. 2013;14(16):2221–36. http://dx.doi.org/10.1517/14656566.2013.832202. [PubMed]
41. Takahashi A, Sasaki H, Kim SJ, Tobisu K, Kakizoe T, Tsukamoto T, et al. Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res. 1994 Aug 1;54(15):4233–7. [PubMed]
42. Zhang X, Yamashita M, Uetsuki H, Kakehi Y. Angiogenesis in renal cell carcinoma: Evaluation of microvessel density, vascular endothelial growth factor and matrix metalloproteinases. Int J Urol. 2002;9(9):509–14. http://dx.doi.org/10.1046/j.1442-2042.2002.00511.x. [PubMed]
43. Rioux-Leclercq N, Fergelot P, Zerrouki S, Leray E, Jouan F, Bellaud P, et al. Plasma level and tissue expression of vascular endothelial growth factor in renal cell carcinoma: a prospective study of 50 cases. Hum Pathol. 2007;38(10):1489–95. http://dx.doi.org/10.1016/j.humpath.2007.02.014. [PubMed]
44. Lin CC, Huang CY, Mong MC, Chan CY, Yin MC. Antiangiogenic Potential of Three Triterpenic Acids in Human Liver Cancer Cells. J Agric Food Chem. 2011;59(2):755–62. http://dx.doi.org/10.1021/jf103904b. [PubMed]
45. Ovesná Z, Vachálková A, Horváthová K, Tóthová D. Pentacyclic triterpenoic acids: new chemoprotective compounds. Minireview. Neoplasma. 2004;51(5):327–33. [PubMed]
46. Sohn KH, Lee HY, Chung HY, Young HS, Yi SY, Kim KW. Anti-angiogenic activity of triterpene acids. Cancer Lett. 1995 Aug 1;94(2):213–8. http://dx.doi.org/10.1016/0304-3835(95)03856-R. [PubMed]
47. Sogno I, Vannini N, Lorusso G, Cammarota R, Noonan DM, Generoso L, et al. Anti-angiogenic activity of a novel class of chemopreventive compounds: oleanic acid terpenoids. Recent Results Cancer Res. 2009;181:209–12. [PubMed]
48. Staunton MJ, Gaffney EF. Tumor type is a determinant of susceptibility to apoptosis. Am J Clin Pathol. 1995;103(3):300–7. http://dx.doi.org/10.1093/ajcp/103.3.300. [PubMed]
49. Qazi AK, Hussain A, Aga MA, Ali S, Taneja SC, Sharma PR, et al. Cell specific apoptosis by RLX is mediated by NFκB in human colon carcinoma HCT-116 cells. BMC Cell Biol. 2014;15:36. http://dx.doi.org/10.1186/1471-2121-15-36. [PMC free article] [PubMed]

Articles from Journal of Kidney Cancer and VHL are provided here courtesy of Codon Publications